Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 1/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27123124 | 0.88 | GPR119 (0.39) | PRKAG1PRKAA1PRKAB1HTR1ATSHR | |
| SCHEMBL27139369 | 0.88 | FFAR4 (0.40) | HTR1ATSHRMGLLHSD11B1 | |
| SCHEMBL29277059 | 0.88 | HSD11B1 (0.39) | HTR1ATSHRNPSR1MGLLHSD11B1 | |
| SCHEMBL30015013 | 0.88 | TSHR (0.43) | TSHRNPSR1LIPGMGLLHSD11B1 | |
| SCHEMBL27123175 | 0.87 | HTR1A (0.39) | HTR1ATSHRNPSR1LIPG | |
| SCHEMBL27125679 | 0.87 | ITGB3 (0.38) | HTR1ATSHRNPSR1MGLLHSD11B1 | |
| SCHEMBL30014221 | 0.87 | ITGB3 (0.38) | HTR1ATSHRNPSR1MGLLHSD11B1 | |
| SCHEMBL28868792 | 0.87 | HSD11B1 (0.40) | TSHRNPSR1LIPGMGLLHSD11B1 | |
| SCHEMBL29201724 | 0.86 | HTR1A (0.38) | HTR1AMGLLHSD11B1 | |
| SCHEMBL27139372 | 0.86 | TSHR (0.41) | TSHRNPSR1LIPGMGLLHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | PRKAG1 515/4885PRKAA1 300/4885PRKAB1 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.